Short-term Treatment of Idiopathic Precocious Puberty with a Long-acting Analogue of Luteinizing Hormone-releasing Hormone

Comite, Florence; Cutler, Gordon B.; Rivier, Jean; Vale, Wylie; Loriaux, D. Lynn; Crowley, William F.

doi:10.1097/00006254-198206000-00023

Cited by 11 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of LHRH a treatment in CAH were identical to those in idiopathic true precocious puberty or precocious puberty associated with intracranial lesions (15,16). The improvement was clearly related to suppression of gonadal function, since LHRH a had no effect on the degree of adrenal suppression.…”

Section: Discussionmentioning

confidence: 82%

“…Vol58«No5 nitol (15). Once dissolved, the compound was stored at -20 C. Each batch was bioassayed before use, and no loss of activity was found after frozen storage for as long as 12 months.…”

Section: Jce and M • 1984mentioning

confidence: 99%

“…Studies have recently shown that a long-acting analog of LHRH (D-Trp 6 -Pro 9 -NEt-LHRH) suppressed pituitary gonadotropins and gonadal sex steroids in children with true precocious puberty (15,16). This study evaluated the addition of the LHRH analog D-Trp 6 -Pro 9 -NEt-LHRH (LHRHa) to a treatment regimen of hydrocortisone and fludrocortisone in four children with true precocious puberty complicating CAH.…”

mentioning

confidence: 99%

See 2 more Smart Citations

True Precocious Puberty Complicating Congenital Adrenal Hyperplasia: Treatment with a Luteinizing Hormone-Releasing Hormone Analog*

Pescovitz

Comite

Cassorla

et al. 1984

The Journal of Clinical Endocrinology & Metabolism

Self Cite

140

View full text Add to dashboard Cite

Congenital adrenal hyperplasia (CAH) is a recognized cause of precocious pseudopuberty. Some children with CAH also develop true precocious puberty with early maturation of the hypothalamic-pituitary-gonadal axis. We have seen four such children (three boys and one girl) who had the diagnosis of CAH made between the ages of 3 and 6 yr. These patients were treated with standard doses of hydrocortisone and fludrocortisone. A diagnosis of true precocious puberty was made because of testicular enlargement in the boys, breast development in the girl, progressive pubic hair development, rapid growth, and rapid bone age maturation. Plasma steroid levels were elevated for age, and gonadotropin levels were within the normal pubertal range, both basally and in response to LHRH stimulation. We treated these children with daily sc injections of a LHRH analog (LHRHa) for 6-18 months in addition to the standard hydrocortisone and fludrocortisone therapy for CAH. LHRHa significantly decreased basal plasma LH and FSH, peak LH and FSH responses to native LHRH, and testosterone levels. Testis size decreased in the males, and breast development regressed in the female. LHRHa therapy led to significant decreases in linear growth rate, ulnar growth rate, and rate of bone age advancement. These results suggest that LHRHa is an effective adjunct to hydrocortisone and fludrocortisone in the treatment of true precocious puberty complicating CAH.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Jce and M • 1984mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

True Precocious Puberty Complicating Congenital Adrenal Hyperplasia: Treatment with a Luteinizing Hormone-Releasing Hormone Analog*

Pescovitz

Comite

Cassorla

et al. 1984

The Journal of Clinical Endocrinology & Metabolism

Self Cite

140

View full text Add to dashboard Cite

show abstract

“…The first reports of successful short-term pituitary-gonadal suppression in CPP patients by GnRH agonists date back to 1981 [8,125,126]. Since then numerous studies have been performed to investigate the psychological, hormonal and auxological effects of GnRH agonists in CPP children and to define the outcome after treatment.…”

Section: Treatment Optionsmentioning

confidence: 99%

Gonadotropin-Releasing Hormone Analogue Treatment for Precocious Puberty

Heger

Sippell

Partsch

2005

Endocrine Development

View full text Add to dashboard Cite

Central precocious puberty (CPP) is the premature onset of puberty due to a precocious activation of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. This condition results in accelerated development of secondary sex characteristics, accelerated bone maturation, impaired final height with disproportioned body appearance and can have a disturbing impact on the psychosocial behavior of children suffering from CPP. It is therefore necessary to assess the hormonal status of children who show pubertal signs before the age 8 years in girls and 9 years in boys. The indication for treatment should be made after evaluating pubertal progression, progression of bone age maturation and final height prognosis, development of reproductive function, and psychosocial adjustment and well-being. This paper summarizes the experience of GnRH agonist treatment, which is momentarily the treatment of choice for central precocious puberty in children.

show abstract

“…In the current study, we attempted to treat the sexual precocity in these children with a long-acting LHRH agonist, D-Trp 6 -Pro 9 -NEt-LHRH (LHRHJ, which has been successfully used to suppress the elevated gonadotropin and sex steroid concentrations and to correct the rapid growth and bone age advancement in girls with idiopathic true precocious puberty (13)(14)(15). The girls with McCune-Albright syndrome had variable responses of serum gonadotropin and estradiol concentrations to treatment with LHRH a .…”

mentioning

confidence: 99%

Variable Response to a Long-Acting Agonist of Luteinizing Hormone-Releasing Hormone in Girls with McCune-Albright Syndrome

Foster

Comite

Pescovitz

et al. 1984

The Journal of Clinical Endocrinology & Metabolism

Self Cite

View full text Add to dashboard Cite

Six girls with McCune-Albright syndrome were treated for at least 2 months with the long-acting LHRH agonist D-Trp6-Pro9-NEt-LHRH, which previously was found to be an effective treatment for true precocious puberty. Nocturnal and LHRH-stimulated serum gonadotropin levels and plasma estradiol levels were measured before treatment and after 2-3 months of treatment. Five of the six girls had no decrease in serum gonadotropin or plasma estradiol levels during therapy, and their pubertal signs were unaffected by treatment. All five of these girls had serum gonadotropin levels that were within or below the normal prepubertal range. The sixth girl, who had gonadotropin levels in the normal pubertal range before treatment, had decreased serum gonadotropin and plasma estradiol levels during 1 yr of LHRH analog therapy. This was associated with cessation of menses and regression of secondary sexual changes. The failure of LHRH analog to modify the course of precocious puberty in the five patients with prepubertal serum gonadotropin concentrations is further evidence that the mechanism of precocious puberty in most girls with McCune-Albright syndrome differs from that in patients with true precocious puberty.

show abstract

Short-term Treatment of Idiopathic Precocious Puberty with a Long-acting Analogue of Luteinizing Hormone-releasing Hormone

Cited by 11 publications

References 0 publications

True Precocious Puberty Complicating Congenital Adrenal Hyperplasia: Treatment with a Luteinizing Hormone-Releasing Hormone Analog*

True Precocious Puberty Complicating Congenital Adrenal Hyperplasia: Treatment with a Luteinizing Hormone-Releasing Hormone Analog*

Gonadotropin-Releasing Hormone Analogue Treatment for Precocious Puberty

Variable Response to a Long-Acting Agonist of Luteinizing Hormone-Releasing Hormone in Girls with McCune-Albright Syndrome

Contact Info

Product

Resources

About